Pulmonary hypertension in chronic obstructive and interstitial lung diseases

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 1795-1804

  Andersen, Charlotte U ^a   Mellemkjær, Søren ^a   Nielsen Kudsk, Jens Erik ^a   Bendstrup, Elisabeth ^a   Hilberg, Ole ^a   Simonsen, Ulf ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

6 min walk test; Biomarkers; Chronic lung disease; NT proBNP; Pulmonary hypertension; Troponin T

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; N(G),N(G) DIMETHYLARGININE; PROSTACYCLIN; ROFLUMILAST; SILDENAFIL; TADALAFIL; TREPROSTINIL; TROPONIN T; VON WILLEBRAND FACTOR;

CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG HALF LIFE; ECHOCARDIOGRAPHY; EXERCISE; FORCED EXPIRATORY VOLUME; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG VENTILATION PERFUSION RATIO; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIX MINUTE WALK TEST;

6MIN WALK TEST; BIOMARKERS; CHRONIC LUNG DISEASE; NT-PROBNP; PULMONARY HYPERTENSION; TROPONIN-T;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY WEDGE PRESSURE;

EID: 84885605987     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.033     Document Type: Review

References (132)

1. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
2. M.M. Hoeper, J.A. Barbera, and R.N. Channick Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension J Am Coll Cardiol 54 2009 S85 S96
3. M. Humbert, O. Sitbon, and A. Chaouat Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era Circulation 122 2010 156 163
4. V.I. Peinado, J.A. Barbera, and J. Ramirez Endothelial dysfunction in pulmonary arteries of patients with mild COPD Am J Physiol 274 1998 L908 L913
5. J.A. Barbera, and I. Blanco Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management Drugs 69 2009 1153 1171
6. A. Giaid, R.P. Michel, and D.J. Stewart Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis Lancet 341 1993 1550 1554
7. I. Blanco, E. Gimeno, and P.A. Munoz Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension Am J Respir Crit Care Med 181 2010 270 278
8. T.A. Dernaika, M. Beavin, and G.T. Kinasewitz Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease Respiration 79 2010 377 382
9. K. Vonbank, R. Ziesche, and T.W. Higenbottam Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD Thorax 58 2003 289 293
10. Global Strategy for the Diagnosis MaPoC Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 [ http://www.goldcopd.org ]
11. R.J. Halbert, J.L. Natoli, and A. Gano Global burden of COPD: systematic review and meta-analysis Eur Respir J 28 2006 523 532
12. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 Am J Respir Crit Care Med 165 2002 277 304
13. R.M. Ron du Bois Strategies for treating idiopathic pulmonary fibrosis Nat Rev Drug Discov 9 2010 129 140
14. G. Raghu, H.R. Collard, and J.J. Egan An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
15. O. Hilberg, U. Simonsen, R. du Bois, and E. Bendstrup Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis Clin Respir J 6 2012 131 143
16. G. Bussone, and L. Mouthon Interstitial lung disease in systemic sclerosis Autoimmun Rev 10 2011 248 255
17. F. Magee, J.L. Wright, B.R. Wiggs, P.D. Pare, and J.C. Hogg Pulmonary vascular structure and function in chronic obstructive pulmonary disease Thorax 43 1988 183 189
18. L. Farkas, J. Gauldie, N.F. Voelkel, and M. Kolb Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors Am J Respir Cell Mol Biol 45 2011 1 15
19. E. Weitzenblum, A. Chaouat, M. Canuet, and R. Kessler Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases Semin Respir Crit Care Med 30 2009 458 470
20. A.T. Dinh-Xuan, T.W. Higenbottam, and C.A. Clelland Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease N Engl J Med 324 1991 1539 1547
21. K.A. Fagan, I.F. McMurtry, and D.M. Rodman Role of endothelin-1 in lung disease Respir Res 2 2001 90 101
22. A.R. Hemnes, A. Zaiman, and H.C. Champion PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation Am J Physiol Lung Cell Mol Physiol 294 2008 L24 L33
23. V.I. Peinado, S. Pizarro, and J.A. Barbera Pulmonary vascular involvement in COPD Chest 134 2008 808 814
24. J.P. Wrobel, B.R. Thompson, and T.J. Williams Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease: a pathophysiologic review J Heart Lung Transplant 31 2012 557 564
25. S.D. Nathan, O.A. Shlobin, and S.D. Barnett Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis Respir Med 102 2008 1305 1310
26. A. Chaouat, A.S. Bugnet, and N. Kadaoui Severe pulmonary hypertension and chronic obstructive pulmonary disease Am J Respir Crit Care Med 172 2005 189 194
27. H. Evers, F. Liehs, and K. Harzbecker Screening of pulmonary hypertension in chronic obstructive pulmonary disease and silicosis by discriminant functions Eur Respir J 5 1992 444 451
28. K.H. Andersen, M. Iversen, and J. Kjaergaard Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease J Heart Lung Transplant 31 2012 373 380
29. C.U. Andersen, S. Mellemkjaer, and O. Hilberg Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test Respir Med 106 2012 875 882
30. N.W. Todd, S. Lavania, and M.H. Park Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia J Heart Lung Transplant 29 2010 188 194
31. J. Hurdman, R. Condliffe, and C.A. Elliot Pulmonary hypertension in COPD: results from the ASPIRE registry Eur Respir J 41 2012 1292 1301
32. S.D. Nathan, O.A. Shlobin, S. Ahmad, S. Urbanek, and S.D. Barnett Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis Chest 131 2007 657 663
33. L. Kiakouama, V. Cottin, and J.C. Glerant Conditions associated with severe carbon monoxide diffusion coefficient reduction Respir Med 105 2011 1248 1256
34. C.R. Lloyd, S.L. Walsh, and D.M. Hansell High-resolution CT of complications of idiopathic fibrotic lung disease Br J Radiol 84 2011 581 592
35. Y. Adir, R. Shachner, O. Amir, and M. Humbert Severe pulmonary hypertension associated with emphysema: a new phenotype? Chest 142 2012 1654 1658
36. V. Cottin, H. Nunes, and P.Y. Brillet Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Eur Respir J 26 2005 586 593
37. V. Cottin, P.J. Le, and G. Prevot Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Eur Respir J 35 2010 105 111
38. J.D. Rich, S.J. Shah, R. Swamy, A. Kamp, and S. Rich The inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice Chest 139 2011 988 993
39. J.D. Roberts, and P.R. Forfia Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography Pulm Circ 1 2011 160 181
40. S.M. Arcasoy, J.D. Christie, and V.A. Ferrari Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease Am J Respir Crit Care Med 167 2003 735 740
41. J. Rizkallah, S.F. Man, and D.D. Sin Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis Chest 135 2009 786 793
42. D.B. Sprunger, A.L. Olson, and T.J. Huie Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease Eur Respir J 39 2012 125 132
43. S. Mellemkjaer, L.B. Ilkjaer, and K.E. Klaaborg Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ten years experience in Denmark Scand Cardiovasc J 40 2006 49 53
44. M.C. LaPointe Molecular regulation of the brain natriuretic peptide gene Peptides 26 2005 944 956
45. J. Mair Biochemistry of B-type natriuretic peptide - where are we now? Clin Chem Lab Med 46 2008 1507 1514
46. A.L. Gerbes, L. Dagnino, T. Nguyen, and M. Nemer Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues J Clin Endocrinol Metab 78 1994 1307 1311
47. M. O'Donoghue, and E. Braunwald Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 7 2010 13 20
48. H.H. Leuchte, C. Neurohr, and R. Baumgartner Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension Am J Respir Crit Care Med 170 2004 360 365
49. H.H. Leuchte, R.A. Baumgartner, and M.E. Nounou Brain natriuretic peptide is a prognostic parameter in chronic lung disease Am J Respir Crit Care Med 173 2006 744 750
50. J.P. Goetze, R. Videbaek, and S. Boesgaard Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease J Heart Lung Transplant 23 2004 80 87
51. C.U. Andersen, S. Mellemkjaer, and J.E. Nielsen-Kudsk Echocardiographic screening for pulmonary hypertension in stable COPD out-patients and NT-proBNP as a rule-out test COPD 9 2012 505 512
52. C.U. Andersen, S. Mellemkjaer, and J.E. Nielsen-Kudsk Diagnostic and prognostic role of biomarkers for pulmonary hypertension in interstitial lung disease Respir Med 106 2012 1749 1755
53. S. Wieshammer, J. Dreyhaupt, B. Basler, and E. Marsovszky NT-proBNP for pulmonologists: not only a rule-out test for systolic heart failure but also a global marker of heart disease Respiration 77 2009 370 380
54. C.L. Chang, S.C. Robinson, and G.D. Mills Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD Thorax 66 2011 764 768
55. A.D. Hoiseth, A. Neukamm, and B.D. Karlsson Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease Thorax 66 2011 775 781
56. C. Rubens, R. Ewert, and M. Halank Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension Chest 120 2001 1562 1569
57. H.J. Reesink, R.C. Meijer, and R. Lutter Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension Circ J 70 2006 1058 1063
58. T. Yamakami, O. Taguchi, and E.C. Gabazza Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise Eur Respir J 10 1997 2055 2060
59. P. Carratu, C. Scoditti, and M. Maniscalco Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension BMC Pulm Med 8 2008 20
60. T. Dimitroulas, G. Giannakoulas, and T. Sfetsios Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension Rheumatology (Oxford) 47 2008 1682 1685
61. M. Gorenflo, C. Zheng, E. Werle, W. Fiehn, and H.E. Ulmer Plasma levels of asymmetrical dimethyl-l-arginine in patients with congenital heart disease and pulmonary hypertension J Cardiovasc Pharmacol 37 2001 489 492
62. S. Pullamsetti, L. Kiss, and H.A. Ghofrani Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension FASEB J 19 2005 1175 1177
63. N. Skoro-Sajer, F. Mittermayer, and A. Panzenboeck Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension Am J Respir Crit Care Med 176 2007 1154 1160
64. M.T. Collados, J. Sandoval, and S. Lopez Characterization of von Willebrand factor in primary pulmonary hypertension Heart Vessels 14 1999 246 252
65. L.H. Caramuru, R.P. Soares, N.Y. Maeda, and A.A. Lopes Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension Clin Appl Thromb Hemost 9 2003 251 258
66. M. Rabinovitch, M. Andrew, and H. Thom Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects Circulation 76 1987 1043 1052
67. D. Shitrit, D. Bendayan, and B. Rudensky Elevation of ELISA d-dimer levels in patients with primary pulmonary hypertension Respiration 69 2002 327 329
68. C.U. Andersen, O. Hilberg, S. Mellemkjær, J.E. Nielsen-Kudsk, and U. Simonsen Apelin and pulmonary hypertenison Pulm Circ 1 2011 334 346
69. J.P. Goetze, J.F. Rehfeld, and J. Carlsen Apelin: a new plasma marker of cardiopulmonary disease Regul Pept 133 2006 134 138
70. C.A. Keller, J.W. Shepard Jr., D.S. Chun, P. Vasquez, and G.F. Dolan Pulmonary hypertension in chronic obstructive pulmonary disease. Multivariate analysis Chest 90 1986 185 192
71. M. Oswald-Mammosser, M. Apprill, P. Bachez, M. Ehrhart, and E. Weitzenblum Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type Respiration 58 1991 304 310
72. S.M. Scharf, M. Iqbal, and C. Keller Hemodynamic characterization of patients with severe emphysema Am J Respir Crit Care Med 166 2002 314 322
73. G. Thabut, G. Dauriat, and J.B. Stern Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation Chest 127 2005 1531 1536
74. M.J. Cuttica, R. Kalhan, and O.A. Shlobin Categorization and impact of pulmonary hypertension in patients with advanced COPD Respir Med 104 2010 1877 1882
75. M.W. Sims, D.J. Margolis, and A.R. Localio Impact of pulmonary artery pressure on exercise function in severe COPD Chest 136 2009 412 419
76. J. Mykland-Hilde, I. Skjørten, and K. Steine Hemodynamic responses to exercise in patients with COPD Eur Respir J 41 2013 1031 1041
77. V. Fayngersh, F. Drakopanagiotakis, M.F. Dennis, and J.R. Klinger Pulmonary hypertension in a stable community-based COPD population Lung 189 2011 377 382
78. H. Mal Prevalence and diagnosis of severe pulmonary hypertension in patients with chronic obstructive pulmonary disease Curr Opin Pulm Med 13 2007 114 119
79. C.J. Lettieri, S.D. Nathan, S.D. Barnett, S. Ahmad, and A.F. Shorr Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis Chest 129 2006 746 752
80. A.F. Shorr, J.L. Wainright, C.S. Cors, C.J. Lettieri, and S.D. Nathan Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Eur Respir J 30 2007 715 721
81. T. Handa, S. Nagai, and S. Miki Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis Chest 129 2006 1246 1252
82. A.F. Shorr, D.L. Helman, D.B. Davies, and S.D. Nathan Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics Eur Respir J 25 2005 783 788
83. D. Launay, L. Mouthon, and E. Hachulla Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease J Rheumatol 34 2007 1005 1011
84. A.L. Chan, R. Rafii, S. Louie, and T.E. Albertson Therapeutic update in idiopathic pulmonary fibrosis Clin Rev Allergy Immunol 44 2013 65 74
85. I.G. Tsiligianni, E. Kosmas, M.T. Van der, and N. Tzanakis Managing comorbidity in COPD: a difficult task Curr Drug Targets 14 2013 158 176
86. B. Burrows, L.J. Kettel, A.H. Niden, M. Rabinowitz, and C.F. Diener Patterns of cardiovascular dysfunction in chronic obstructive lung disease N Engl J Med 286 1972 912 918
87. M. Finlay, H.C. Middleton, M.D. Peake, and P. Howard Cardiac output, pulmonary hypertension, hypoxaemia and survival in patients with chronic obstructive airways disease Eur J Respir Dis 64 1983 252 263
88. M. Oswald-Mammosser, E. Weitzenblum, and E. Quoix Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure Chest 107 1995 1193 1198
89. G.A. Traver, M.G. Cline, and B. Burrows Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study Am Rev Respir Dis 119 1979 895 902
90. E. Weitzenblum, C. Hirth, and A. Ducolone Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease Thorax 36 1981 752 758
91. B. Chang, F.M. Wigley, B. White, and R.A. Wise Scleroderma patients with combined pulmonary hypertension and interstitial lung disease J Rheumatol 30 2003 2398 2405
92. K. Hamada, S. Nagai, and S. Tanaka Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis Chest 131 2007 650 656
93. J. Hurdman, R. Condliffe, and C.A. Elliot ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre Eur Respir J 39 2012 945 955
94. D. Polomis, J.R. Runo, and K.C. Meyer Pulmonary hypertension in interstitial lung disease Curr Opin Pulm Med 14 2008 462 469
95. K. Vonbank, G.C. Funk, and B. Marzluf Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD Wien Klin Wochenschr 120 2008 749 755
96. C. Pynnaert, M. Lamotte, and R. Naeije Aerobic exercise capacity in COPD patients with and without pulmonary hypertension Respir Med 104 2010 121 126
97. B.G. Boerrigter, H.J. Bogaard, and P. Trip Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension Chest 142 2012 1166 1174
98. A.K. Boutou, G.G. Pitsiou, and I. Trigonis Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension Respirology 16 2011 451 458
99. S. Glaser, O. Noga, and B. Koch Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis Respir Med 103 2009 317 324
100. A.M. Modrykamien, R. Gudavalli, K. McCarthy, and J. Parambil Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis Respir Care 55 2010 584 588
101. J.J. Swigris, A.L. Olson, and O.A. Shlobin Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis Respirology 16 2011 439 445
102. D.A. Zisman, A.S. Karlamangla, and D.J. Ross High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis Chest 132 2007 773 779
103. A. Shujaat, A.A. Bajwa, and J.D. Cury Pulmonary hypertension secondary to COPD Pulm Med 2012 2012 203952
104. J.D. Corbin, A. Beasley, M.A. Blount, and S.H. Francis High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors Biochem Biophys Res Commun 334 2005 930 938
105. C.U. Andersen, M.J. Mulvany, and U. Simonsen Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats Eur J Pharmacol 510 2005 87 96
106. A. Sebkhi, J.W. Strange, S.C. Phillips, J. Wharton, and M.R. Wilkins Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension Circulation 107 2003 3230 3235
107. L. Zhao, N.A. Mason, and N.W. Morrell Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428
108. J. Milara, G. Juan, and J.L. Ortiz Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil Eur J Pharm Sci 39 2010 363 372
109. H.A. Ghofrani, R. Wiedemann, and F. Rose Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial Lancet 360 2002 895 900
110. B.P. Madden, M. Allenby, T.K. Loke, and A. Sheth A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease Vascul Pharmacol 44 2006 372 376
111. H.R. Collard, K.J. Anstrom, M.I. Schwarz, and D.A. Zisman Sildenafil improves walk distance in idiopathic pulmonary fibrosis Chest 131 2007 897 899
112. H. Rietema, S. Holverda, and H.J. Bogaard Sildenafil treatment in COPD does not affect stroke volume or exercise capacity Eur Respir J 31 2008 759 764
113. D.A. Zisman, M. Schwarz, and K.J. Anstrom A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N Engl J Med 363 2010 620 628
114. N. Vignon-Zellweger, S. Heiden, T. Miyauchi, and N. Emoto Endothelin and endothelin receptors in the renal and cardiovascular systems Life Sci 91 2012 490 500
115. S. Eddahibi, B. Raffestin, M. Clozel, M. Levame, and S. Adnot Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats Am J Physiol 268 1995 H828 H835
116. S. Schroll, M. Arzt, and D. Sebah Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan Respir Physiol Neurobiol 170 2010 32 36
117. J. Milara, E. Gabarda, and G. Juan Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries Eur Respir J 39 2012 927 938
118. K. Ahmadi-Simab, B. Hellmich, and W.L. Gross Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease Eur J Clin Invest 36 Suppl. 3 2006 44 48
119. O.A. Minai, D. Sahoo, J.T. Chapman, and A.C. Mehta Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease Respir Med 102 2008 1015 1020
120. D. Stolz, H. Rasch, and A. Linka A randomised, controlled trial of bosentan in severe COPD Eur Respir J 32 2008 619 628
121. G. Valerio, P. Bracciale, and D.A. Grazia Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease Ther Adv Respir Dis 3 2009 15 21
122. H. Olschewski, H.A. Ghofrani, and D. Walmrath Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis Am J Respir Crit Care Med 160 1999 600 607
123. L. Farkas, D. Farkas, and K. Ask VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats J Clin Invest 119 2009 1298 1311
124. C.U. Andersen, L.H. Markvardsen, O. Hilberg, and U. Simonsen Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension Respir Med 103 2009 1663 1671
125. J. Cortijo, A. Iranzo, and X. Milara Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury Br J Pharmacol 156 2009 534 544
126. M. Izikki, B. Raffestin, and J. Klar Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats J Pharmacol Exp Ther 330 2009 54 62
127. R.E. Girgis, D. Li, and X. Zhan Attenuation of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Heart Circ Physiol 285 2003 H938 H945
128. T.M. Lee, C.C. Chen, H.N. Shen, and N.C. Chang Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension Clin Sci (Lond) 116 2009 497 505
129. L. Lahousse, D.W. Loth, and G.F. Joos Statins, systemic inflammation and risk of death in COPD: the Rotterdam study Pulm Pharmacol Ther 26 2013 212 217
130. T. Rasekaba, A.L. Lee, M.T. Naughton, T.J. Williams, and A.E. Holland The six-minute walk test: a useful metric for the cardiopulmonary patient Intern Med J 39 2009 495 501
131. V. Mainguy, S. Malenfant, and A.S. Neyron Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension Eur Respir J 42 2 2013 Aug 425 434
132. A. Vonk-Noordegraaf, and R. Souza Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension? Am J Cardiol 110 2012 25S 31S